Making A Meaningful Impact In AAV

At this year’s Meeting on the Mesa, Andy Holt, Chief Commercial Officer at Viralgen, shared updates on three strategic initiatives designed to streamline gene therapy development. First, the company has brought plasmid DNA manufacturing in-house, enabling tighter integration with its Rep/Cap and helper plasmid capabilities. Second, its development services now leverage a platform-based model that draws insights from thousands of AAV batches—helping reduce risk and accelerate timelines. Third, for therapies targeting larger patient populations, Viralgen is offering new ways to significantly lower cost of goods (COGs) per patient. Holt also introduced the latest iterations of the Aava™ platform—Gen 2.0 (Mendi) and Gen 3.0 (Iturri)—each engineered to deliver greater predictability, faster turnaround, and deeper analytical insights.